RAPT Therapeutics Inc (RAPT) - Cash Flow Conversion Efficiency
Based on the latest financial reports, RAPT Therapeutics Inc (RAPT) has a cash flow conversion efficiency ratio of -0.082x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-12.46 Million) by net assets ($151.98 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See RAPT Therapeutics Inc (RAPT) defensive interval to measure how many days the company can operate on defensive assets alone.
RAPT Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2017–2024)
This chart illustrates how RAPT Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
RAPT Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of RAPT Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Beijing Caishikou Department Store Co Ltd
SHG:605599
|
0.091x |
|
Wuxi Best Precision Machinery Co Ltd
SHE:300580
|
0.036x |
|
TBO Tek Ltd
NSE:TBOTEK
|
0.021x |
|
PC Connection Inc
NASDAQ:CNXN
|
0.015x |
|
Natco Pharma Limited
NSE:NATCOPHARM
|
0.138x |
|
Greatech Technology Bhd
KLSE:0208
|
0.011x |
|
Okeanis Eco Tankers Corp.
NYSE:ECO
|
0.069x |
|
German American Bancorp Inc
NASDAQ:GABC
|
0.032x |
Annual Cash Flow Conversion Efficiency for RAPT Therapeutics Inc (2017–2024)
The table below shows the annual cash flow conversion efficiency of RAPT Therapeutics Inc from 2017 to 2024. For the full company profile with market capitalisation and key ratios, see RAPT Therapeutics Inc market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $189.90 Million | $-83.30 Million | -0.439x | +33.54% |
| 2023-12-31 | $147.03 Million | $-97.05 Million | -0.660x | -128.65% |
| 2022-12-31 | $245.17 Million | $-70.77 Million | -0.289x | +11.84% |
| 2021-12-31 | $186.38 Million | $-61.03 Million | -0.327x | +15.76% |
| 2020-12-31 | $104.18 Million | $-40.49 Million | -0.389x | +19.89% |
| 2019-12-31 | $73.12 Million | $-35.47 Million | -0.485x | +5.78% |
| 2018-12-31 | $64.00 Million | $-32.95 Million | -0.515x | -218.47% |
| 2017-12-31 | $-62.41 Million | $-27.12 Million | 0.435x | -- |
About RAPT Therapeutics Inc
RAPT Therapeutics, Inc. operates as a clinical-stage immunology-based biopharmaceutical company that focuses on the discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) an… Read more